Intellia Therapeutics (NTLA)Prices 4.795M Share Common Offering at $36.50/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/1/2026
- Wall Street dips as rising Treasury yields outweigh software gains
- Fed’s Jefferson sees no urgency for another rate increase
- Oil prices rise $3 after China suspends fuel exports
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
- Anthropic targets mid-November for public debut - report
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- Micron Technology (MU) Tops Q4 EPS by $2.26, Offers Guidance
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
December 1, 2020 9:30 PM ESTCAMBRIDGE, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced today the pricing of an underwritten public offering of 4,794,521 shares of its common stock at a public offering price of $36.50 per share. Intellia also granted the underwriters a 30-day option to purchase up to an additional 719,178 shares of its common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to... More
